Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And closer to FDA APPROVAL. THOUGH WITH RIGHT TO TRY, probably MUCH FASTER.
LETS GET SOME GREEN THIS WEEK!
1. RIGHT TO TRY.
Now see that’s interesting. Why kind of property. When did they buy it?
So again. What are you alleging? Be specific. Enumerate, please.
Trompete, that actually made me chuckle.
Why don’t you just tell us? This is what I’m talking about. Say what you mean to say and not throwing shade. That’s all ANYONE does on this thread anymore.
A disappointment.
Have a good day. Off to see Sherlock Gnome! Maybe he’ll have some
Ideas!!!
That’s why all 181M shares will vote for RS and AS. They may lose shares as part of RS but get 500m Warrants. Vote no on both.
So you are saying Oppenheimer and Roth were both duped and this isn’t a real company?
Have a good weekend, board.
So DCTH says market opportunity with FDA approval for both therapies is between $372,000,000 - $1,200,000,000.
Right to Try cracks that market opportunity wide open, and you say it will be worth $270,000???
Do you honestly think before you type?
These products may very well be commercially available this year. Both these products meet the criteria for RIGHT TO TRY in the US.
Remember, economies of scale! You don’t think they signed up for increased supply of their signature drug for the heck of it, do you?
Amen.
Catch you all some time next week.
I don’t have an issue if there is action. If there is something to action, then do it.
Good luck to you. I hope this gets better.
My take:
The guy spoke like DCTH writes their filings; the person who recorded it was part of the Bulgarian contingent; the Delcath.org site is a rebrand from stocktwits—though I don’t even know why they got their panties in a bunch last year.
Injunction for what, lol. ???
Discuss what, the veracity of the recording? What year? About what?
Enough pearl clutching; you eat this up.
What’s this “accounting issue”? Ugh.
The halcyon day’s for sure! I could use some ACME dynamite for DCTH right about now.
Both posts are fierce!
Good to have you back. Now
Turnip won’t cry that we’re one in the same.
Let’s turn green soon.
Ugh. Kill Me Now.
1. DARK HORSE. RIGHT TO TRY. Passed in Senate. Passed in House. Back to Senate for final vote (likely, first vote was 96-4) and then to the President who will sign it into law.
What does this mean?
Ocular Melanoma and Intrahepatic cholangiocarcinoma (ICC) are among the most prevalent and lethal forms of cancer. It appears RIGHT TO TRY would put Ocular Melanoma (FOCUS trial) and Intrahepatic Cholangiocarcinoma (ICC) in play this year.
DCTH believes their Ocular Melanoma therapy and Intrahepatic cholangiocarcinoma therapy, combined, believe the potential market opportunity is between $452 MILLION - $1.3 BILLION annually:
2, Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
10K CONFIRMATION:
During 2017, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales.
http://delcath.com/investors-news/
Hahaha. If DCTH ever goes to $.0175, I will buy you a pair.
No. I don’t think you’ve made your point.
I don’t know if your intentions are altruistic or if you have a horse in the race. Again, I am just providing my honest opinion. If you’ve got the goods, drive a stake through DCTH and be done with it.
Oh I think more companies than we think are aware of what’s going on.
If it isn’t a buyout or partnership, she’s trying to PIPE. If that happens at this PPS, it won’t be very good for us.
My short answer is I am here to
make money.
Please understand I bear no animus to what you are doing. If there is an end game, why wait? If the proof is here, take action. In a way, you might be doing all of us a favor.
"It's only for people who say, 'I understand the risk. I know this drug is not fully approved. It may not help me, but my doctor and the drug company think it could, and I want to try,'" she said. "Basically, if the FDA says that a drug is safe enough to be used in trials on humans, then it's safe enough for a dying person to make their own choice about whether or not they would like to try it when they can't get into a clinical trial."
https://www.cnn.com/2018/03/22/health/federal-right-to-try-explainer/index.html
CHECK OUT THEEEEESE SHORTS!!!
https://goo.gl/images/hCeD4T
Someone’s getting nervous.
Great; now I have Peter Cetera in my head.
If you would leave me now...
Are you going to yell at him, James? After all, you said you bought DCTH BECAUSE OF HIS POSTS just two days ago, lol.
Are you, or anyone else, going to hire an attorney and go after these guys? This talk about an empty office, half of which is subleased I understand, has all of the hallmarks of The Untouchables, only it’s not Capone and it doesn’t really have teeth, does it?
We’re getting hammered; naked shorting appears to be everywhere; are HG and Ayerton in cahoots?; throw in a Greek shipping consortium; the Geddy Lee Gang; and now Bulgarians? I can tolerate Sam’s circular logic; in fact, it’s kinda cute. It’s like if Yoda had an uncle, but unfortunately, was intoxicated most of the time.
If there is incontrovertible proof that something nefarious is going on, PM me and I’ll hire an attorney. It will save me from having to spend additional time and money chasing down the Baba Yaga.
This whole board is starting to sound like a bunch of crazies. DCTH has the opportunity for not one, but TWO drug protocols to bypass the traditional FDA approval and access U.S. MARKETS THIS YEAR.
WHAT THE HECK ARE WE HERE FOR, IF NOT FOR THIS???
Keep Sleeping Shorts...
DARK HORSE. Right to Try Legislation. House PASSED 3/21/18. This will pass in Senate shortly and Trump will sign into law.
So what does this mean?
Ocular Melanoma and Intrahepatic cholangiocarcinoma (ICC) are among the most prevalent and lethal forms of cancer. While I need to read the legislation, it appears RIGHT TO TRY would put Ocular Melanoma (FOCUS trial) and Intrahepatic Cholangiocarcinoma (ICC) squarely under this law.
DCTH believes their Ocular Melanoma therapy and Intrahepatic cholangiocarcinoma therapy, combined, believe the potential market opportunity is between $452 MILLION - $1.3 BILLION annually.
1. Orphaned (SPA) Ocular Melanoma (FOCUS) - $80-$200M
2. Orphaned (SPA) Intrahepatic cholangiocarcinoma (ICC) $372 - $930M
A bigger question is whether, because they are SPA, the 7 year period of exclusivity period would still apply?
http://delcath.com/investors-news/
----
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
-----
Ahem...
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
10K CONFIRMATION:
During 2017, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales.
http://delcath.com/investors-news/
I AM DELIGHTED DR. PEDDER IS ON BOARD!
DARK HORSE. Right to Try Legislation. House PASSED 3/21/18. This will pass in Senate shortly and Trump will sign into law.
So what does this mean?
Ocular Melanoma and Intrahepatic cholangiocarcinoma (ICC) are among the most prevalent and lethal forms of cancer. While I need to read the legislation, it appears RIGHT TO TRY would put Ocular Melanoma (FOCUS trial) and Intrahepatic Cholangiocarcinoma (ICC) squarely under this law.
DCTH believes their Ocular Melanoma therapy and Intrahepatic cholangiocarcinoma therapy, combined, believe the potential market opportunity is between $452 MILLION - $1.3 BILLION annually.
1. Orphaned (SPA) Ocular Melanoma (FOCUS) - $80-$200M
2. Orphaned (SPA) Intrahepatic cholangiocarcinoma (ICC) $372 - $930M
A bigger question is whether, because they are SPA, the 7 year period of exclusivity period would still apply?
http://delcath.com/investors-news/
----
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Simon Pedder, Ph.D., a scientist and pharmaceutical executive with a greater than 30-year career in drug development, has joined the Delcath Board of Directors effective November 14, 2017.
Dr. Pedder currently serves as Chief Business and Strategy Officer at Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.During his long career in drug development, Dr. Pedder has held several leadership positions including President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Executive Officer and Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of the Hepatitis Franchise at Hoffmann-LaRoche.
http://delcath.com/reuters-news/?id=2317872
-----
Ahem...
Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
“We are particularly pleased to be working with a supplier of Tillomed’s caliber and experience as it establishes firm control over our melphalan supply chain in Europe and, over time, will provide economies of scale", noted Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath.
ECONOMIES OF SCALE: A proportionate saving in costs gained by an increased level of production.
Read: Additional supply is needed to match the increased demand for the CHEMSAT therapy.
10K CONFIRMATION:
During 2017, Delcath added 7 employees to support clinical trial implementations in the EU and United States and to meet the demands of commercial sales.
http://delcath.com/investors-news/
$270K?????
Goodness, your math is worse than your timing for FDA approvals!
FOCUS AND ICC, combined, are an annual market opportunity of $372M-$1.2B. You realize it’s both ocular melanoma and ICC?
Sam, not sure you understand the implications of what just happened.
I am pulling down the bill and reading today. I want to make sure DCTH’s therapy would be included.
If yes, RS or not, I don’t think funding will be an issue. Maybe the cancellation of Oppenheimer Conference was a blessing in disguise.
If you look at the presentation from Roth Conference, Ocular Melanoma (FOCUS) and ICC are both SPA and fall would fall under Right To Try. Though still requiring approval in senate (passed 96-4) first time, it will require a second vote and President Trump WILL sign into law. I assumed this would be done around October, not April!
I am going to reach out to IR for a statement.